Evidence map›Paper›PMID 32647324›Full record

ArticleLeukemia2020

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.

Lydia Scarfò, Thomas Chatzikonstantinou, Gian Matteo Rigolin, Giulia Quaresmini, Marina Motta, Candida Vitale, Jose Antonio Garcia-Marco, José Ángel Hernández-Rivas, Fatima Mirás, Mónica Baile and 72 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 174 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
174citing papers in PubMed, 10 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

174 citing papers in PubMed, 10 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Article
  19. Article
  20. Article

114 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

82 authors.

Lydia Scarfò *Università Vita-Salute San Raffaele and IRCC Ospedale San Raffaele, Milan, Italy.
Thomas Chatzikonstantinou *Hematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
Gian Matteo Rigolin *Hematology Section, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Giulia QuaresminiUSC Ematologia, ASST PAPA GIOVANNI XXIII, Bergamo, Italy.
Marina MottaS.C. Ematologia, ASST Spedali Civili, Brescia, Italy.
Candida VitaleUniversity Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Jose Antonio Garcia-MarcoHematology Department, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.ORCID http://orcid.org/0000-0002-8993-5982
José Ángel Hernández-RivasHospital Universitario Infanta Leonor, Madrid Universidad Complutense, Madrid, Spain.ORCID http://orcid.org/0000-0003-4550-757X
Fatima MirásHospital Universitario 12 de Octubre, Madrid, Spain.
Mónica BaileServicio de Hematología del Complejo Asistencial Universitario de Salamanca-IBSAL, Salamanca, Spain.
Juan MarquetHematology Department, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Carsten U NiemannDepartment of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.ORCID http://orcid.org/0000-0001-9880-5242
Gianluigi RedaU.O.C. Ematologia, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy.
Talha MunirSt James's University Hospital, Leeds, UK.
Eva GimenoHematology Department Hospital del Mar, Barcelona, Spain.
Monia MarchettiHematology Dpt, Az Osp SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy.ORCID http://orcid.org/0000-0001-7615-0572
Francesca Maria QuagliaDepartment of Medicine, Section of Hematology, University of Verona, Verona, Italy.
Marzia VarettoniDivision of Haematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Julio DelgadoDept. of Hematology, Hospital Clinic, IDIBAPS, Barcelona, Spain.
Sunil IyengarDepartment of Haemato-Oncology, Royal Marsden Hospital, London, UK.
Ann JanssensUniversitaire Ziekenhuizen Leuven, Leuven, Belgium.
Roberto MarascaHematology Unit, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy.
Angela FerrariHematology, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.
Carolina Cuéllar-GarcíaHematology Unit, Consorci Sanitari Terrassa Hospital, Terrassa, Spain.ORCID http://orcid.org/0000-0002-1475-5143
Gilad ItchakiRabin Medical Center, Beilinson Hospital; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Martin Špaček1st Department of Medicine-Department of Hematology, First Faculty of Medicine, Charles University and General Hospital in Prague, Prague, Czech Republic.
Lorenzo De PaoliDivision of Hematology, Department of Translational Medicine, University of Eastern Piedmont, Novara, Italy.
Luca LaurentiDipartimento Scienze Radiologiche ed Ematologiche, Divisione di Ematologia Fondazione Policlinico universitario A Gemelli, Roma, Italy.
Mark-David LevinDepartment of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
Enrico ListaStruttura Semplice Dipartimentale di Ematologia, Presidio Ospedaliero Santa Chiara, Trento, Italy.
Francesca R MauroHematology, Department of Translational and Precision Medicine, Sapienza University, Policlinico Umberto I, Rome, Italy.
Martin ŠimkovičDepartment of Internal Medicine-Haematology, University Hospital and Medical School Hradec Kralove, Hradec Kralove, Czech Republic.
Ellen Van Der SpekInternal Medicine, Rijnstate Hospital, Arnhem, The Netherlands.
Elisabeth VandenbergheDepartment of Haematology, St James Hospital and Trinity College Dublin, Dublin, Ireland.
Livio TrentinHematology Unit, University of Padua, Padua, Italy.ORCID http://orcid.org/0000-0003-1222-6149
Ewa Wasik-SzczepanekDept. Hematooncology and Bone Marrow Transplantation, Medical University in Lublin, Lublin, Poland.
Rosa RuchlemerDepartment of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel.
Dominique BronInst J Bordet (ULB), Brussels, Belgium.
Maria Rosaria De PaolisUOC Ematologia PO Vito Fazzi Lecce, Lecce, Italy.
Giovanni Del PoetaCattedra di Ematologia Dipartimento di Biomedicina e Prevenzione, Università Tor Vergata Roma, Rome, Italy.
Lucia FarinaDivision of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy.
Myriam FogliettaSC Ematologia, AO S. Croce e Carle, Cuneo, Italy.
Massimo GentileUOC Ematologia AO Cosenza, Cosenza, Italy.
Yair HerishanuDepartment of Hematology, Tel Aviv Sourasky Medical Center, and Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
Tobias HeroldDepartment of Medicine III, University Hospital, LMU Munich, Munich, Germany.ORCID http://orcid.org/0000-0002-9615-9432
Ozren JaksicDepartment of Hematology, University hospital Dubrava, Zagreb, Croatia.
Arnon P KaterDep of Hematology, Cancer Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Sabina KerstingDepartment of Hematology, Haga Hospital, The Hague, The Netherlands.
Lara MalerbaHematology Unit, Azienda Ospedaliera "Ospedali Riuniti Marche Nord", Pesaro, Italy.
Lorella OrsucciDivision of Hematology II, San Giovanni Battista Hospital, Torino, Italy.
Viola Maria PopovColentina Clinical Hospital Bucharest, Bucharest, Romania.ORCID http://orcid.org/0000-0002-1200-379X
Paolo SportolettiInstitute of Hematology and Center for Hemato-Oncological Research, Ospedale S. Maria della Misericordia, University of Perugia, Perugia, Italy.ORCID http://orcid.org/0000-0002-5630-9862
Mohamed YassinNational Center for Cancer Care and Research Doha, Doha, Qatar.
Barbara PocaliDivision of Hematology and Stem Cell Transplantation Unit, Cardarelli Hospital, Naples, Italy.
Gabor Barna1st Department of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary.
Annalisa ChiarenzaDivision of Hematology, Policlinico, Department of Surgery and Medical Specialties, University of Catania, Catania, Italy.
Gimena Dos SantosHospital de Clinicas, Montevideo, Uruguay.ORCID http://orcid.org/0000-0002-9337-1833
Eugene NikitinDepartment of Hematology, Oncology, and Chemotherapy, S. P. Botkin's City Hospital, Moscow, Russia.
Martin AndresDepartment of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.ORCID http://orcid.org/0000-0001-9891-2988
Maria Dimou1st First Propedeutic Department of Internal Medicine, Hematology Unit, Laikon General Hospital, National and Kapodistrian University of Athens, Medical School of Athens, Athens, Greece.ORCID http://orcid.org/0000-0001-8197-9895
Michael DoubekUniversity Hospital and CEITEC MU Brno, Brno, Czech Republic.ORCID http://orcid.org/0000-0002-1269-6282
Alicia EnricoHematology Area, Hospital Italiano La Plata, La Plata, Argentina.
Yervand HakobyanHematology Center after Prof. Yeolyan MH RA, Yerevan, Armenia.
Olga KalashnikovaFirst State Pavlov Medical University of Saint-Petersburg, Raisa Gorbacheva Memorial Institute for Children Oncology, Hematology and Transplantation Russia, Saint-Petersburg, Russia.
Macarena Ortiz ParejaCarlos Haya, Málaga, Spain.
Maria PapaioannouHematology Unit, 1st Dept of Internal Medicine, AUTH, AHEPA Hospital, Thessaloniki, Greece.
Davide RossiLaboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
Nimish ShahNorfolk & Norwich University NHS Foundation Trust, Norwich, UK.
Amit ShresthaHematology Unit, Nepal Cancer Hospital & Research Centre, Lalitpur, Nepal.
Oana Stanca"Carol Davila" University of Medicine and Pharmacy, Hematology Clinic, Coltea Clinical Hospital, Bucharest, Romania.
Niki StavroyianniHematology Department and HCT Unit, G. Papanicolaou Hospital, Thessaloniki, Greece.
Vladimir StrugovHematology Almazov National Medical Research Centre, St. Petersburg, Russia.
Constantine TamPeter MacCallum Cancer Centre and University of Melbourne, Victoria, Australia.
Mihnea ZdrengheaDepartment of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy and Ion Chiricuta Oncology Institute, Cluj-Napoca, Romania.
Marta CosciaUniversity Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
Kostas StamatopoulosInstitute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece. kostas.stamatopoulos@certh.gr.
Giuseppe RossiS.C. Ematologia, ASST Spedali Civili, Brescia, Italy.
Alessandro RambaldiUSC Ematologia, ASST PAPA GIOVANNI XXIII, Bergamo, Italy.ORCID http://orcid.org/0000-0002-3739-7502
Emili' MontserratDept. of Hematology, Hospital Clinic, IDIBAPS, Barcelona, Spain.
Robin FoàHematology, Department of Translational and Precision Medicine, Sapienza University, Policlinico Umberto I, Rome, Italy.ORCID http://orcid.org/0000-0002-5021-3026
Antonio CuneoHematology Section, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Paolo GhiaUniversità Vita-Salute San Raffaele and IRCC Ospedale San Raffaele, Milan, Italy. ghia.paolo@hsr.it.ORCID http://orcid.org/0000-0003-3750-7342

Funding

Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) Investigator Grant #20246Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research) Special Program on Metastatic Disease - 5 per mille #21198
6 · The paper itself

Abstract

Chronic lymphocytic leukemia (CLL) is a disease of the elderly, characterized by immunodeficiency. Hence, patients with CLL might be considered more susceptible to severe complications from COVID-19. We undertook this retrospective international multicenter study to characterize the course of COVID-19 in patients with CLL and identify potential predictors of outcome. Of 190 patients with CLL and confirmed COVID-19 diagnosed between 28/03/2020 and 22/05/2020, 151 (79%) presented with severe COVID-19 (need of oxygen and/or intensive care admission). Severe COVID-19 was associated with more advanced age (≥65 years) (odds ratio 3.72 [95% CI 1.79-7.71]). Only 60 patients (39.7%) with severe COVID-19 were receiving or had recent (≤12 months) treatment for CLL at the time of COVID-19 versus 30/39 (76.9%) patients with mild disease. Hospitalization rate for severe COVID-19 was lower (p < 0.05) for patients on ibrutinib versus those on other regimens or off treatment. Of 151 patients with severe disease, 55 (36.4%) succumbed versus only 1/38 (2.6%) with mild disease; age and comorbidities did not impact on mortality. In CLL, (1) COVID-19 severity increases with age; (2) antileukemic treatment (particularly BTK inhibitors) appears to exert a protective effect; (3) age and comorbidities did not impact on mortality, alluding to a relevant role of CLL and immunodeficiency.

Indexed as

BetacoronavirusAdenineAgedAged, 80 and overAge FactorsAntineoplastic AgentsComorbidityCoronavirus InfectionsCOVID-19FemaleHumansLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedPandemicsPiperidinesAdenineAntineoplastic AgentsibrutinibPiperidinesProtein Kinase InhibitorsPyrazolesPyrimidines

Identifiers

PMID32647324
PMCPMC7347048

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.